Sitagliptin reduces FAP-activity and increases intact FGF21 levels in patients with newly detected glucose abnormalities-Reference-Cited by-同舟云学术

Sitagliptin reduces FAP-activity and increases intact FGF21 levels in patients with newly detected glucose abnormalities

Published:2022-10 Issue: Volume:556 Page:111738
ISSN:0303-7207
Container-title:Molecular and Cellular Endocrinology
language:en
Short-container-title:Molecular and Cellular Endocrinology

Author:

Pedersen Anne K.N.^ORCID,Hage Camilla^ORCID,Jessen Niels,Mellbin Linda,Bjerre Mette^ORCID

Publisher

Elsevier BV

Subject

Endocrinology,Molecular Biology,Biochemistry

Reference64 articles.

1. Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein α;Aertgeerts;J. Biol. Chem.,2005

2. Serum fibroblast growth factor 21 was elevated in subjects with type 2 diabetes mellitus and was associated with the presence of carotid artery plaques;An;Diabetes Res. Clin. Pract.,2012

3. Circulating fibroblast growth factors as metabolic regulators - a critical appraisal;Angelin;Cell Metabol.,2012

4. Fibroblast activation protein is a GH target: a prospective study of patients with acromegaly before and after treatment;Arlien-Søborg;J. Clin. Endocrinol. Metab.,2020

5. Improved glycemic control due to sitagliptin is not related to cortisol or the surrogate marker IGFBP-1 for hepatic insulin sensitivity. Growth Horm;Arnetz;IGF Res.,2015

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metformin Improves the Prerequisites for FGF21 Signaling in Patients With Type 2 Diabetes;The Journal of Clinical Endocrinology & Metabolism;2023-09-30

2. Total serum FGF-21 levels positively relate to visceral adiposity differently from its functional intact form;Frontiers in Endocrinology;2023-06-20